Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

We expect Sanofi to remain on solid financial footing. It closed 2024 with a debt/EBITDA ratio of 1.7 times. The company generates stable cash flows from a diverse product portfolio, which should ...

Dupixent is a key top-line driver for Sanofi and Regeneron. During first-half 2024, Sanofi recorded €6.14 billion from Dupixent product sales, indicating 27% year-over-year growth.

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%.

--Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has approved Dupixent ® as an add-on maintenance treatment for adolescent patients aged 12 ...